A national mass tort education & case connection resourceCALL (888) 468-4608
A national mass tort education & case connection resourceCALL (888) 468-4608
Skip to content
Mass Tort AmericaEDUCATING THE PEOPLE

LITIGATION NEWS & INFORMATION

Depo-Provera October 29 Fund Order: Why Approval Is Not a Payment Notice

✓ No fee unless you win✓ Free & confidential review✓ Board-certified trial attorney
Folder, settlement-fund vault and closed envelope illustrating the October 29 Depo-Provera fund order, not payment approval.

Last reviewed: November 15, 2026

“Qualified settlement fund” does not mean your Depo-Provera claim has qualified for a payment. The court used that term when it approved two funds on October 29. It describes the funds’ legal status, not the result of an individual claim review.

For someone waiting after a meningioma diagnosis, three questions remain: does my claim qualify, what amount has been allocated, and what must happen before I receive anything? The new order helps explain the money-handling process. It cannot answer those questions for you.

Judge M. Casey Rodgers approved the Depo-Provera Qualified Settlement Fund and the separate Common Benefit Qualified Settlement Fund in MDL 3140. Below is a closer reading of the order and its agreements, with the passages to ask counsel about. Our Depo-Provera hub covers the underlying litigation; this is specifically about the October fund approval.

The document to look at first

Approval comes first in the document: paragraph 1 establishes the funds under agreements dated October 26. But approval is not a statement that all money has arrived. For that distinction, read Exhibit A, section 2-2. Pfizer deposits proceeds as they become due under the confidential Master Settlement Agreement, or MSA, and the fund holds them pending further disbursement instructions from the parties and administrator.

The administrator is Randall L. Sansom, CPA. We covered his appointment in the September administration article. The new order requires a federally insured depository institution, quarterly reporting to the court and continued court jurisdiction. None of those provisions is a quarterly check schedule.

There is no balance statement in this order. There is also no automatic claimant interest payment: paragraph 5 applies fund earnings first to applicable taxes, then administration costs, then beneficiaries if excess remains. That priority concerns the fund’s earnings, not advice about taxes on your own award.

Even the end of the fund is controlled by the court. Paragraph 6 ties the administrator’s discharge to final distribution and court termination; it does not specify a finish date that a claimant can use for household budgeting.

Follow the money on paper

The word “qualified” in the fund’s name describes the fund, not a determination that every claimant qualifies. Paragraph 1 of the order places the funds under section 468B of the Internal Revenue Code and the applicable Treasury regulations. It is not a list of approved individual claims.

If counsel tells you an amount has been allocated, ask what would come out before payment. Exhibit A, section 3-6, provides for distributions under the MSA to a settling claimant’s lawyer, or the claimant if self-represented, and lienholders. Not every reader will have the same lien questions. Your own accounting is what matters.

The common-benefit fund is different. Exhibit B, section 1-2, says it holds attorneys’ fees and expenses assessed or held back from proceeds under court orders. Section 2-2 holds those payments pending a future court order for disbursement to claimant counsel. This is not a second individual award to add to a quoted figure.

Ask which assessments actually apply to you rather than guessing a percentage from the existence of this fund. The public order does not calculate your take-home amount, and it does not set one payment date for all claimants.

A useful question for counsel

A practical request is: “Please tell me whether my claim is accepted, whether an amount has been allocated, and what is still unresolved before distribution.” If there is an accounting, ask which deductions apply and which figures remain unsettled. These are suggested questions, not additional tasks ordered by the court.

The point is to get an answer about your claim. A copy of the fund order cannot show your registration status or award. CMO 14 identifies November 30, 2026 as the program registration deadline understood by the court, so ask counsel to confirm registration if you are unsure. Fund approval does not complete registration.

Someone without counsel should get individual advice about eligibility and filing deadlines rather than assume the program date governs a new lawsuit. Our registration explanation discusses that difference.

Finally, the settlement is not an admission: CMO 14 says defendants admit no fault or liability in connection with it. The fund order is not a finding that the drug caused an individual claimant’s meningioma. There is still no guarantee of compensation or a payment date from these documents.

Attorney Advertising. General information only, not legal or medical advice. Reading this does not create an attorney-client relationship. Compensation, payment dates and outcomes are not guaranteed. Medical decisions belong with your treating clinician.

Sources

Robert B. Baker, Board-Certified Civil Trial Attorney
Claims reviewed by Baker Legal Team
Robert B. Baker, Esq., B.C.S. — Board-Certified Civil Trial Lawyer. 30+ years of trial experience, more than $400 million recovered for clients. About Robert Baker →

This website provides general information. Your circumstances require an individual review.

Still have questions?

Start with a free case review, with no obligation.

Call NowFree Case Review
Call (888) 468-4608See If You Qualify